This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Toll-like receptor 9 (TLR9) or TLR3 adjuvants to promote cancer vaccine-induced effector T cell expansion	<p>Mouse studies suggest TLR9 or TLR3 ligands can enhance cancer vaccine-induced effector T cell expansion. In mice, vaccines formulated with the TLR9 ligand CpG or the TLR3 ligand poly(I:C) expanded effector T cell populations more than vaccines formulated with other adjuvants or without adjuvant. In mouse xenograft models of melanoma, vaccination using TLR9 or TLR3 ligands as adjuvants prolonged survival and slowed tumor growth and increased effector T cell infiltration into tumors compared with vaccination using other adjuvants. Next steps include combining these adjuvants with other formulations to enhance the antitumor immune response and including an antigen delivery system to improve spatiotemporal control over immune system activation.</p> <p>SciBX 6(42); doi:10.1038/scibx.2013.1207 Published online Oct. 31, 2013</p>	Unpatented; licensing status not applicable	<p>Perret, R. <i>et al. Cancer Res.</i>; published online Sept. 18, 2013; doi:10.1158/0008-5472.CAN-13-0875 Contact: Rachel Perret, University of Lausanne, Epalinges, Switzerland e-mail: rachel.perret@unil.ch</p>